NA HOMOLCE TO BECOME 3RD SITE FOR VISABL-VT

18 February 2026 – Melbourne, Australia (**17 February 2026** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc.** (**Company** or **Imricor**) (**ASX: IMR**) is pleased to announce that, with local Ethics Committee approval, the Na Homolce Hospital in Prague, Czech Republic (**Na Homolce**) is to be the third site to join the VISABL-VT clinical trial.

The Principal Investigator (PI) for VISABL-VT at Na Homolce is Professor Petr Neužil, MD. Professor Neužil is the Head of Cardiology and the Director of the Cardiac Arrhythmia Service at Na Homolce, and he is a world-renowned cardiac electrophysiologist. Na Homolce Hospital performs up to 3500 catheterisation procedures each year.

Also participating in VISABL-VT at Na Homolce is Dr Vivek Reddy, MD. Dr Reddy is an internationally recognised cardiac electrophysiologist and Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and the Mount Sinai Health System in New York, USA. Across his career, Dr. Reddy has been a prominent leader in translating next-generation rhythm therapies into real-world practice through high-impact clinical programs and multicentre research.

Petr Neužil and **Vivek Reddy** at Na Homolce will join **Gerhard Hindricks** and **Felix Hohendanner** at Charité in Berlin, along with **Michiel Kemme** at Amsterdam UMC in the trial.

Imricor's Chair and CEO, Steve Wedan, commented: "Ventricular tachycardia (VT) ablations are among the most complex and time-consuming procedures performed by electrophysiologists worldwide. Despite decades of advances in mapping and ablation technologies, outcomes across VT patients remain disappointing. The difficulties associated with VT ablations and the promise that MRI guidance offers to these procedures are well-known. And the names of the world-leading doctors from the first three sites participating in VISABL-VT tells you something about how important the transformation is that we are enabling.

"Following the groundbreaking work performed at Amsterdam UMC last year, we are now expanding into key sites of influence with leading key opinion leaders in the field. I couldn't be more excited to welcome Professor Petr Neužil and Dr Vivek Reddy, and the world-class team at Na Homolce, to the VISABL-VT study. This is a major step toward bringing MRI-guided interventions into the limelight and into the mainstream."

Imricor's Vice President of Corporate Strategy, Nick Corkill, added: "Starting with atrial flutter was an important steppingstone for interventional cardiac MRI (iCMR), and VT is the next big step. In an environment that is free of all X-ray radiation for patients and staff, MRI guidance enables the visualization of arrhythmogenic substrates that are hidden to other imaging modalities, opening the door for shorter procedures and better outcomes. It is exciting to see iCMR spread to yet another country in Europe, and especially with such an important reference site."

ENDS
Authorised for release by Steve Wedan, Executive Chair, President, and CEO

Media and Investor Relations Contacts:

Simon Hinsley
Executive Director, NWR
simon@nwrcommunications.com.au
+61 401 909 653

Nick Corkill
VP Corporate Strategy, Imricor
nick.corkill@imricor.com
+61 450 475 633

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance imaging (MRI) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MRI's superior imaging capabilities.

Imricor's Products

Imricor is a pioneer and world leader in developing MRI-compatible products for cardiac catheter ablation procedures. The Company's products include capital equipment, such as the NorthStar® Mapping System and the Advantage-MR® EP Recorder/Stimulator. Single-use devices include a variety of ablation catheters, diagnostic catheters, steerable sheaths, and other tools used for cardiac ablations.

Imricor's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand. US FDA approval is in process, and further approvals in other geographies such as Australia are being planned.

Foreign Ownership Restrictions

Imricor's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU. sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.